



PDA Europe

Georg Roessling, PhD
Senior Vice President
Niederbarnimstr. 24
16548 Glienicke
Germany

Tel: + 49 33056 43 6879
Fax: +49 33056 43 6884
Email: roessling@pda.org
www.pda.org

OFFICERS

Chair:
John Shabushnig, PhD
Pfizer

Chair-Elect:
Maik Jornitz
Sartorius Stedim Biotech

Secretary:
Rebecca Devine, PhD
Regulatory Consultant

Treasurer:
Anders Vinther, PhD
Genentech

Immediate Past Chair:
Vincent Anicetti
Genentech

President:
Robert Myers

DIRECTORS

Harold Baseman
ValSource

Véronique Davoust, PhD
Pfizer

Lothar Hartmann, PhD
F. Hoffman-La Roche

Louise Johnson
Aptuit

Stefan Köhler
AstraZeneca

Steven Mendivil
Amgen

Michael Sadowski
Baxter Healthcare

Amy Scott-Billman
GlaxoSmithKline

Junko Sasaki
Sumitomo Pharmaceuticals

Christopher Smalley
Wyeth

Laura Thoma, PharmD
University of Tennessee

Martin Van Trieste
Amgen

Acting Editor, *PDA Journal of
Pharmaceutical Science
and Technology*:

Richard V. Levy, PhD
Parenteral Drug Association

27 May 2009

European Medicines Agency (EMA)
Inspections Sector
London
gmp@emea.europa.eu

European Commission
Pharmaceuticals Unit
Brussels
entr-gmp@ec.europa.eu

Ref: Concept Paper on the Implementation of ICH Q10;
doc EMEA/INS/GMP/34212/2009; 11 March 2009
Deadline for comments: 30 June 2009

To: Responsible Person: European Commission, Pharm. Unit
Responsible Person: EMA Inspections Sector

PDA is pleased to provide comments on the concept paper for implementation of ICH Q10 in the EU GMP guide. As ICH Q10 is not a standalone document, special focus should be given to enabling principles of Quality Risk Management (see ICH Q9) and Knowledge Management. For this reason we recommend the following changes in Section 4 of the concept paper (added text in *italics*):

Section 4. Recommendation:

2) Clearer guidance on the handling and investigations of deviations, Corrective and Preventive action and change control *taking into account the principles of quality risk management and knowledge management.*

3) Emphasising the role of senior management in ensuring that there is an effective Quality Management System *that is knowledge-based and enables risk-based decision making* to support GMP.

Thank you for the opportunity to support appropriate and useful guidance. Please contact me, or James Lyda of my staff (lyda@pda.org), if you have any questions.

With very best regards,

Georg Roessling, Ph.D.
Senior VP, PDA Europe
Roessling@pda.org

cc: S. Rönninger, S. Mendvil, J. Lyda, R. Levy, R. Dana,